Syndax Pharmaceuticals Inc
SNDXNasdaq
$22.80
↑ +0.4%Jul 17 close · end-of-day
Price
1Y↑ +146.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$2.0B
P/E
—
P/S
9.3
P/B
48.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$217.2M
Net Income (TTM)
-$243.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-102.9%
Net Margin
-112.0%
ROE
-584.4%
ROIC
-446.4%
Debt / Equity
8.4
Net Cash
$2.1M
Return 1Y
+135.8%
Company profile
Syndax Pharmaceuticals, Inc. develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein.
- CEO
- Michael A. Metzger
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- Massachusetts
- Website
- syndax.com
Management & directors
- Metzger Michael AChief Executive Officer
- Botwood Nicholas A.J.Head of R&D, CMO
- Goldan Keith A.Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
SNDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$64.9M↑ +223.6%
Diluted EPS-$0.48↓ -51.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $139.7M | $0.00 | $0.00 | $23.7M | $172.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$71.4M | $26.2M | -$151.8M | -$230.0M | -$339.7M | -$273.1M |
| Net income | -$73.2M | $24.9M | -$149.3M | -$209.4M | -$318.8M | -$285.4M |
| Diluted EPS | -$1.87 | $0.46 | -$2.46 | -$2.98 | -$3.72 | -$3.29 |
| Operating cash flow | -$71.3M | $29.1M | -$133.7M | -$160.6M | -$274.9M | -$323.0M |
| Free cash flow | -$71.3M | $29.0M | -$133.7M | -$160.6M | -$274.9M | -$323.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -4708.2% | 18.8% | — | — | -1434.4% | -158.4% |
| Net margin | -4822.5% | 17.8% | — | — | -1346.3% | -165.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $12.5M | $7.7M | $20.0M | $38.0M | $45.9M | $68.5M | $64.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$74.2M | -$89.6M | -$96.4M | -$83.8M | -$69.4M | -$57.4M | -$62.5M | -$34.2M |
| Net income | -$68.1M | -$84.1M | -$94.2M | -$84.8M | -$71.8M | -$60.7M | -$68.0M | -$42.7M |
| Diluted EPS | -$0.80 | -$0.98 | -$1.09 | -$0.98 | -$0.83 | -$0.70 | -$0.78 | -$0.48 |
| Operating cash flow | -$71.6M | -$62.3M | -$57.4M | -$95.2M | -$87.8M | -$70.5M | -$69.5M | -$50.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2120.5% | -716.6% | -1254.8% | -417.9% | -182.7% | -125.2% | -91.3% | -52.7% |
| Net margin | -1944.7% | -673.0% | -1226.7% | -423.3% | -189.3% | -132.4% | -99.3% | -65.8% |
Company news
Jul 17, 2026
Jul 14, 2026
- 6d agoSyndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Pushmarketbeat.com
- 6d agoWall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Betfinance.yahoo.com
- 6d agoSyndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Eventfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A· Chief Executive Officer | Sale | 32,375 | $24.24 | $784,776.48 | filing |
| 2026-07-08 | Metzger Michael A· Chief Executive Officer | Option exercise | 32,375 | $6.38 | $206,552.50 | filing |
| 2026-06-12 | Botwood Nicholas A.J.· Head of R&D, CMO | Sale | 31,235 | $18.14 | $566,602.90 | filing |
| 2026-06-12 | Botwood Nicholas A.J.· Head of R&D, CMO | Option exercise | 31,235 | $13.82 | $431,667.70 | filing |
| 2026-06-11 | Botwood Nicholas A.J.· Head of R&D, CMO | Sale | 34,280 | $18.00 | $617,040.00 | filing |
| 2026-06-11 | Botwood Nicholas A.J.· Head of R&D, CMO | Option exercise | 22,515 | $13.82 | $311,157.30 | filing |
| 2026-06-01 | Metzger Michael A· Chief Executive Officer | Sale | 6,847 | $18.99 | $130,024.53 | filing |
| 2026-06-01 | Goldan Keith A.· Chief Financial Officer | Sale | 1,177 | $18.99 | $22,351.23 | filing |
| 2026-02-09 | Metzger Michael A· Chief Executive Officer | Sale | 17,159 | $21.03 | $360,819.45 | filing |
| 2026-02-09 | Goldan Keith A.· Chief Financial Officer | Sale | 3,410 | $21.03 | $71,705.48 | filing |
| 2026-02-06 | Metzger Michael A· Chief Executive Officer | Sale | 7,412 | $20.62 | $152,835.44 | filing |
| 2026-02-06 | Goldan Keith A.· Chief Financial Officer | Sale | 2,082 | $20.62 | $42,930.84 | filing |
| 2026-02-04 | Metzger Michael A· Chief Executive Officer | Award | 144,600 | $0.00 | $0.00 | filing |
| 2026-02-04 | Metzger Michael A· Chief Executive Officer | Award | 73,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Goldan Keith A.· Chief Financial Officer | Award | 21,500 | $0.00 | $0.00 | filing |
| 2026-02-04 | Goldan Keith A.· Chief Financial Officer | Award | 30,750 | $0.00 | $0.00 | filing |
| 2026-02-04 | Jarrett Jennifer | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Huber Martin H. Jr. | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Botwood Nicholas A.J.· Head of R&D, CMO | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Botwood Nicholas A.J.· Head of R&D, CMO | Award | 36,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Podlesak Dennis | Award | 48,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Rizo Aleksandra | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Katkin Keith | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Legault Pierre | Award | 24,000 | $0.00 | $0.00 | filing |
| 2026-01-30 | Goldan Keith A.· Chief Financial Officer | J | 1,219 | $8.48 | $10,337.12 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.